NCT03172117View on ClinicalTrials.gov

Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL

human umbilical cord blood derived mesenchymal stem cells

"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"

OTHER

Normal saline 2mL

Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Medipost Co Ltd.

INDUSTRY

NCT03172117 - Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial. | Biotech Hunter | Biotech Hunter